Chandigarh: PGI will be one of the sites for the second and third phase Covovax – vaccines against Covid-19 – in children.
There will be 10 sites like that in the country and PGI is one of them.
“I have been contacted for the same thing.
But we must get permission from the Ethics Committee of the Institute.
After this is done, we will be able to find out how many subjects can be taken from our site for the trial,” said Prof.
Madhu Gupta, the main research researcher at PGI , The total sample size will be 920 and 460 each is for the age group of 12 years and 17 years and 2 years and 11 years of age group.
The source said about 100 subjects would be permitted in PGI.
Last year, PGI was registered as one of 17 experimental sites to do the second and third phase of the covishield human clinical trial, vaccine developed by Oxford University.
The trial will begin by the Indian Institute Institute during this month when SII will request approval from drug controllers in India for Covovax.
Recombinant nanoparticle protein-based vaccines -nvxcov2373 – developed by American biotechnology companies Novavax have been labeled as Covovax in India.
This will be the fourth Covid-19 vaccine for clinical trials for children in India.
Children will be followed up for six months after they were traced with two Covovax shots after a gap of 21 days.
This vaccine is expected to be launched at the end of the year.